Showing results (151-160 of 387) with videos related to

Sort By:
Pageof 39
Yeast (Chichester, England)|June 1, 1993
Alteration of cell population structure due to cell lysis in Saccharomyces cerevisiae cells overexpressing the GAL4 geneE Martegani, L Brambilla, D Porro, et al.
Journal of Biological Regulators and Homeostatic Agents|December 2, 2020
Management of gunshot wound to the lumbosacral spine in a 17-year-old girl without neurological impairmentR Bassani, C Morselli, M Agnoletto, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 16, 2005
Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumourA Morabito, R Longo, G Carillio, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|September 19, 2007
Distraction osteogenesis in the surgical treatment of craniostenosis: a comparison of internal and external craniofacial distractor devicesS Pelo, G Gasparini, A Di Petrillo, et al.
Breast Cancer Research and Treatment|March 14, 2001
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapyG Gasparini, E Biganzoli, E Bonoldi, et al.
Breast Cancer Research and Treatment|January 1, 1994
A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinomaG Gasparini, P Boracchi, P Bevilacqua, et al.
Tumori|October 31, 1984
Monoclonal gammopathy (IgM-k) in a patient with Burkitt's type lymphoblastic lymphomaE Bajetta, G Gasparini, G Facchetti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 10, 2014
Dermatological consultations in an observation unit of an emergency department in ItalyF Drago, G Gasparini, A Signori, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancerG Gasparini, F Pozza, R Dittadi, et al.
American Journal of Clinical Oncology|February 1, 1991
Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trialG Gasparini, S Dal Fior, G A Panizzoni, et al.
Pageof 39